Search Results

Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.

• Authors : Tokuyasu, Daiki¹ (AUTHOR); Suzuki, Shigeaki¹ (AUTHOR) ; Uzawa, Akiyuki² (AUTHOR)

Subjects: *MYASTHENIA gravis; *ECULIZUMAB; *CLINICAL trialsJAPAN

• Source: Annals of Clinical & Translational Neurology. May2024, Vol. 11 Issue 5, p1338-1346. 9p.

Record details

The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab.

• Authors : Tanaka, Kazuki; Adams, Brigitte; Aris, Alvaro Madrid

Subjects: DRUG efficacy; GLOMERULAR filtration rate; GENERIC drug substitution

• Source: Pediatric Nephrology. Apr2021, Vol. 36 Issue 4, p889-898. 10p. 1 Diagram, 3 Charts, 3 Graphs.

Record details

Speaker Abstracts.

Subjects: *ORPHAN drugs; *ECULIZUMAB; *PAROXYSMAL hemoglobinuria

• Source: Basic & Clinical Pharmacology & Toxicology. Oct2013 Supplement 2, Vol. 113, p4-6. 3p.

Record details

Novel targeted C3 inhibitor pegcetacoplan for paroxysmal nocturnal hemoglobinuria.

• Authors : Xu, Bo¹ (AUTHOR)

Subjects: *PAROXYSMAL hemoglobinuria; *ECULIZUMAB; *CLINICAL trials

• Source: Clinical & Experimental Medicine. Jul2023, Vol. 23 Issue 3, p717-726. 10p.

Record details

Randomized multicenter noninferiority phase III clinical trial of the first biosimilar of eculizumab.

• Authors : Kulagin, Alexander D.¹ (AUTHOR) ; Ptushkin, Vadim V.² (AUTHOR); Lukina, Elena A.³ (AUTHOR)

Subjects: *PAROXYSMAL hemoglobinuria; *ECULIZUMAB; *CLINICAL trials

• Source: Annals of Hematology. Nov2021, Vol. 100 Issue 11, p2689-2698. 10p.

Record details

Phase 3 Trial Enrollment Approved in China for Samsung Bioepsis' Biosimilar Eculizumab

• Source: Legal Monitor Worldwide. January 13, 2020

Record details

Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data.

• Authors : Panse, Jens (AUTHOR); Wilson, Koo (AUTHOR); Fishman, Jesse (AUTHOR)

Subjects: QUALITY of life; CLINICAL trials; CHRONIC diseases

• Source: European Journal of Haematology. Jul2023, Vol. 111 Issue 1, p72-83. 12p.

Record details

Findings on Guillain-Barre Syndrome Detailed by Investigators at Chiba University (Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial)

• Source: Obesity, Fitness & Wellness Week. June 16, 2018, 768

Record details

Researchers from Tenon Hospital Report Recent Findings in Hemolytic Uremic Syndrome (Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry)

• Source: Health & Medicine Week. November 29, 2019, 6017

Record details

Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.

• Authors : Risitano, Antonio M.^1,2,3 (AUTHOR); Peffault de Latour, Regis^3,4 (AUTHOR); Marano, Luana¹ (AUTHOR)

Subjects: *PAROXYSMAL hemoglobinuria; *ECULIZUMAB; *CLINICAL trials

• Source: Seminars in Immunology. Jan2022, Vol. 59, pN.PAG-N.PAG. 1p.

Record details